Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review

被引：82

作者：

Fleming, P. ^{[1
]}

Roubille, C. ^{[2
]}

Richer, V. ^{[3
]}

Starnino, T. ^{[4
]}

McCourt, C. ^{[5
]}

McFarlane, A. ^{[6
]}

Siu, S. ^{[7
]}

Kraft, J. ^{[8
]}

Lynde, C. ^{[8
]}

Pope, J. E. ^{[7
]}

Keeling, S. ^{[6
]}

Dutz, J. ^{[5
]}

Bessette, L. ^{[9
]}

Bissonnette, R. ^{[10
]}

Haraoui, B. ^{[11
,12
]}

Gulliver, W. P. ^{[13
]}

机构：

[1] Univ Toronto, Div Dermatol, Toronto, ON, Canada

[2] Univ Montreal Hosp Res Ctr CRCHUM, Notre Dame Hosp, Montreal, PQ, Canada

[3] Hop St Luc, Dept Med, Dermatol Serv, Montreal, PQ H2X 1P1, Canada

[4] Univ Montreal, Sacre Coeur Hosp Montreal, Montreal, PQ, Canada

[5] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC V5Z 1M9, Canada

[6] Univ Alberta, Div Rheumatol, Edmonton, AB, Canada

[7] Western Univ, Div Rheumatol, Dept Med, St Josephs Hlth Care, London, ON, Canada

[8] Lynde Dermatol, Markham, ON, Canada

[9] Ctr Hosp Univ Quebec, Dept Med, Rheumat Dis Unit, Quebec City, PQ, Canada

[10] Innovaderm Res, Montreal, PQ, Canada

[11] CHUM, Dept Med, Rheumat Dis Unit, Montreal, PQ, Canada

[12] Inst Rhumatol Montreal, Montreal, PQ, Canada

[13] Mem Univ Newfoundland, Dept Med, St John, NF, Canada

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2015年 / 29卷 / 06期

关键词：

QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; MODERATE; FATIGUE; RISK; ETANERCEPT; CYTOKINES; MORBIDITY; STRESSOR;

D O I：

10.1111/jdv.12909

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

BackgroundTwenty to fifty percent of patients with psoriasis have depressive symptoms. ObjectiveTo describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL-12/23i]) on depressive symptoms in patients with psoriasis. MethodsElectronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis. ResultsOf the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24weeks from baseline was 3.1 with ustekinumab (P<0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self-Rating Depression Scale at 12weeks from baseline was -6.7 with adalimumab vs. -1.5 with placebo. In a trial evaluating etanercept, the between-group difference at 12weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined. ConclusionAdalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.

引用

页码：1063 / 1070

页数：8

共 34 条

[1]

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study [J].